Verici Dx plc (VRCDF)

Market Cap	10.56M +27.7%
Revenue (ttm)	1.91M -55.9%
Net Income	-7.62M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	31,370
Open	2.910
Previous Close	0.003
Day's Range	2.910 - 2.910
52-Week Range	0.003 - 2.910
Beta	1.52
RSI	94.78
Earnings Date	Apr 14, 2026

About Verici Dx

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functiona...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 15
• Stock Exchange: OTCMKTS
• Ticker Symbol: VRCDF

Financial Performance

In 2024, Verici Dx's revenue was $3.34 million, an increase of 229.62% compared to the previous year's $1.01 million. Losses were -$5.87 million, -32.75% less than in 2023.